Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 113.8 HKD -2.65% Market Closed
Market Cap: 155.1B HKD
Have any thoughts about
Beigene Ltd?
Write Note

Beigene Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beigene Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Beigene Ltd
HKEX:6160
Change in Working Capital
-ÂĄ12.8B
CAGR 3-Years
-278%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Change in Working Capital
ÂĄ490.4m
CAGR 3-Years
N/A
CAGR 5-Years
75%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Change in Working Capital
-ÂĄ3.9B
CAGR 3-Years
-70%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Change in Working Capital
-ÂĄ1.1B
CAGR 3-Years
-13%
CAGR 5-Years
-10%
CAGR 10-Years
-22%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Change in Working Capital
-ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
-24%
CAGR 10-Years
-33%
Imeik Technology Development Co Ltd
SZSE:300896
Change in Working Capital
-ÂĄ496.4m
CAGR 3-Years
-43%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
No Stocks Found

Beigene Ltd
Glance View

Market Cap
156.9B HKD
Industry
Biotechnology

Beigene Ltd. has emerged as a formidable player in the global biopharmaceutical landscape, primarily focusing on the discovery and development of innovative medicines to treat cancer. Founded in 2010, the company has quickly established itself with a strong commitment to addressing the significant unmet medical needs in oncology. Headquartered in Beijing, China, Beigene's expansive R&D efforts are complemented by an extensive portfolio of targeted therapies, including BTK inhibitors and PD-1 antibodies, which have garnered attention for their effectiveness in treating various malignancies. What sets Beigene apart is its strategic emphasis on global collaboration, combining scientific expertise with a patient-centric approach to accelerate the development of breakthrough therapies. Investors find Beigene's aggressive growth strategy particularly appealing, as the company not only pursues internal drug development but also engages in partnerships and collaborations to enhance its pipeline and market reach. Recently, Beigene's acquisition of the global rights to several key therapies has bolstered its position in the U.S. market, giving it the resources necessary to compete on a larger scale. With its dual listing on both the Nasdaq and the Hong Kong Stock Exchange, Beigene showcases its ambition and adaptability in a rapidly evolving sector. As the company continues to innovate and expand its footprint, it stands poised to capitalize on the increasing global demand for cancer treatments, making it an intriguing prospect for long-term investors seeking exposure to the dynamic biotech industry.

Intrinsic Value
164.36 HKD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Beigene Ltd's Change in Working Capital?
Change in Working Capital
-12.8B CNY

Based on the financial report for Dec 31, 2023, Beigene Ltd's Change in Working Capital amounts to -12.8B CNY.

What is Beigene Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-54%

Over the last year, the Change in Working Capital growth was -33%. The average annual Change in Working Capital growth rates for Beigene Ltd have been -278% over the past three years , -54% over the past five years .

Back to Top